Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
once this breaks below 2 bucks... look out below. we could be back under a buck in no time.
ooops, heading further south. Once this breaks two bucks look out below. But, a real CEO would know what to do.
agree. but, current mis-management is to arrogant to see the problem. When the stock dips below a buck then the board might grow some and make the changes.
a new sales team for starters
fire the complacent ones.
entice competition amongst the remaining salesfolk
get rid of the dead wood so to speak.
a spark of an all out campaign to produce sales!
a new beginning, a Rush for dollar amount goals!
git git go and now sales team!!
I have been saying all along, NEW CEO, NEW VISION. Selling assets and a reverse split that was very poorly managed. We need a seasoned veteran businessman to lead this company. Time for change.
ALQA a chain of very painful events. ouch
First- they sold the TheraBond® 3D Antimicrobial Barrier Product Line. No!
Second it was the 10-1 reverse split. red flag
And then an earnings loss of (-.79) disaster!
Now the stock fell to a paultry 2.17 or .21 cents in my book. terrible
Someone needs to jump start the pipeline! whatever.
it does not "have the ingredients". This is a very poorly managed company and the only reason it has a low float is that they did a 10/1 reverse split. They did the reverse split at .35 cents, so it is down 30% since the reverse. This company does have some potential, even with terrible management, to return to higher prices. Just wait until the shorts get done and make their money.
Low Float stocks been flying...this has the ingredients
That is what makes a market. You think higher I think lower. My thinking is this, there is no change in strategy and leadership. The same leadership that saw this nearly de-listed and only saved from that by a poorly managed reverse split. So, the only change since the reverse split is a lower price. My guess is that shorts will hit this soon and we might be able to pick up shares a lot lower level. Do you have any reason to think that it is going higher? Based on what? Please share. My opinion is that they need to make a change at CEO and hire a professional in the business field to run this company.
2.47 HOD...More tomorrow imo
Ok..do yer plan..I'll do mine
Bought Shares At 2.13
yes it is, but, we have no idea how many shares they have issued to insiders since the reverse split. They are poorly managed and have been selling assets to survive. I would wait until the shorts are finished with this thing before I would be, just MHO.
Super Low O/S Bio-Play
I am surprised it is still above 2 dollars (.20 pre-split). The company has not changed any strategy. So, I am still thinking shorts will come in soon and finish this off. I am looking for 1 dollar are less in the next 30 days.
please respond with share structure TIA
I would think melt down. You still have a company that has sold assets to survive, a ceo that is not a business man, a stock at a lower price that it was before the reverse split. Give it some time... I believe there is a strong short position about to happen and will bring the price lower. Just MHO
New Low floater...has big upside in todays bio-market
Wait for the shorts to do their job and pushing this down. The reverse took place at .35 and it closed at 3.00. that is a .50 cent drop. That is about a 15% drop in price. Let the dust settle.
buying now would be dangerous, IMHO. They did a 10/1 reverse at .35 cents. It closed at 3.00. That is a drop. I would think that there will be a lot of shorting going on for the next few days. I would suggest waiting until it hits 2.00 to 2.50 before buying.
They still have the same mismanagement at the top, they sold assets to survive. The story has not changed, this is a prime target for shorting.
The company has great products, they just need better management. Be patient and let the dust settle.
buyers are back..... could see a nice move now and fill the gap
buyers are back..... could see a nice move now and fill the gap
Finally. We need to get that cloud out of the way. Now if they would announce a new CEO, someone with business experience, it would be huge. Once the stock settles, around 2 to 2.50, would be a good time to take a hard look at this company.
Alliqua BioMedical, Inc. Announces 1-for-10 Reverse Stock Split
effective close of business 10/5/17
Is it just me, but on the day the stock is pumped back above 40 cents, Barton Bradford, the chief operating officer, sells 67,000 shares? The management is lining their own pockets, the company is selling assets to survive, what next? What is terrible about this entire ordeal is that the company has great products and could succeed.
Dear Board of Directors:
Please do the reverse and get it over with.
Please hire real corporate management. The CEO and C/O need to go.
I agree with you ABOUT. This will only continue downward until they do the reverse split. They need to get it over with. I would wait until the reverse split is done before I would jump in.
This is rocking. About to break HOD
CELGENE CORPORATION Owns 18.8% Of Company
https://ih.advfn.com/p.php?pid=nmona&article=75124199
this company has great products, but terrible management. Imagine what this could be if they would put a real CEO in who understands business. Right now we are heading to .20, maybe less. When the board does the reverse split they also need to split with the CEO and bring in someone with a successful track record in company management.
So, here it is in writing. They are doubling the authorized shares, meaning dilution and authorized a reverse split between 3/1 to 13/1 meaning more dilution. The action will keep the company listed, but will, I believe, push the price down.
(1) A proposal to ratify the filing and effectiveness of the certificate of amendment to the Company’s amended and restated certificate of incorporation (as amended) (the “Certificate of Incorporation”) filed with the Secretary of State of the State of Delaware on May 6, 2016 (the “Share Increase Amendment”), which effected an increase in the number of authorized shares of the Company’s common stock from 45,714,286 shares to 95,000,000 shares (the “Ratification Proposal”).
(2) A proposal to authorize the Company’s board of directors, in its discretion, but prior to the annual meeting of the Company’s stockholders in 2018, to amend the Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1-for-3 to 1-for-13, such ratio to be determined by the board of directors and included in a public announcement (the “Reverse Stock Split Proposal”).
(3) A proposal to approve an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of any of the foregoing proposals (the “Adjournment Proposal”).
I am also anxious to hear about the reverse split
09-13-17 Shareholder meeting news? Did they release any info yet on what decision was made in the meeting that started 2 hours ago (9amEST)?
traders
Buy at 30 sell at 35 for a quick buck or two.
i would lean your way on this. This is just a case of bad managment, the board should make a change now. Eventually they will have to. They need a CEO who knows how to succeed and build. Am guessing this is not his gift. But, once the reverse is done, it is the last bullet in their arsenal. They have to produce and grow and they will be delisted. My opinion is everyone should wait until the dust settles before buying.
So they do a 10-1 reverse split. By the 18th it will shares will probably be around .20 each so that would take you to $2.00 but it will just get shorted straight back under 1.00 in less than the minimum over 1.00 required. I think they are going to go for the max proposal of 1-13 which will buy them enough time to stay on the Nasdaq until the next notification that they are under 1.00. Maybe EPS will be positive in November and the stock can turn around from being shorted all day.
i do not think zero, but, no reason to buy until after the reverse split. I would suggest waiting until the dust settles. I would expect a 10/1 reverse split and then a price drop to about 2.00. They I would be a buyer.
Losing %3 per day, at this rate zero in a week
Last 8K puts updates in writing of executives final compensation in the event of employment continuation and termination, looks like a set up for a sale of the Company. Why else would such details be updated and put in writing? Buyout or merger agreement to follow, mark post.
good, let's get this issue behind us. I am guessing a 10/1. That would put the price above 3 bucks. Most reverse splits see the price push downward after. Let's say it goes back to 2 bucks... great buying opportunity at that price.
September 13th is when the shareholder meeting will occur that defines what the terms of the split will be.
CELG has a market value of 103B and I think they will buy ALQA which has a market value of 22 million
I cannot find the news. When is the reverse split and what is the ratio?
Followers
|
66
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
4871
|
Created
|
05/22/06
|
Type
|
Free
|
Moderators |
Alliqua's core transdermal delivery technology platform is designed to deliver drugs and other beneficial ingredients through the skin. Transdermal delivery has multiple advantages over conventional oral and injection delivery including:
In addition, Alliqua's patch technology can be utilized for the delivery of many drugs, including various proteins that have, until now, necessitated injections or intravenous infusions.
Alliqua intends to capitalize on its technology's other intrinsic benefits in various market verticals in the healthcare industry, including: wound healing, medical diagnostics and cosmeceuticals.
Alliqua, through its wholly owned subsidiary AquaMed, develops, manufactures and markets electron-beam cross-linked sheet gels for use as transdermal delivery of medication, topical application of non-prescription drugs, wound/burn dressings with and without active ingredients, components in certain medical devices, treatments, cosmetics and other commercial products.
Hydrogels are gel-like or colloidal substances made of water and solids. They can be created chemically (through a combination of ultra violet cross-linking and chemical interface), or by mixing polymer and water, and then exposing it to an electron beam creating a "sheet" of water. Alliqua believes that its hydrogels have a competitive advantage, in part due to the following product characteristics: painless adhesion to the human body, stability of form and composition, purity, reproducibility (manufacturing high quality product on a consistent basis), compatibility with active ingredients, and high water content.
Many of the products of Alliqua's competition feature physical characteristics which Alliqua believes are less desirable than its own hydrogels
Subsidiary | Products |
---|---|
Alliqua Biomedical | PHN Patch |
Hydress + Plus | |
Hydress | |
Aquamed Technologies | Contract Manufacturing Services |
Electrode Gel | |
Sheet Hydrogels | |
HepaLife Biosystems | HepaMate® |
RECENT HEADLINES
Thursday, November 15, 2012
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |